(+)-JQ1

For research use only.

Catalog No.S7110

230 publications

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's (+)-JQ1 has been cited by 230 publications

Purity & Quality Control

Choose Selective Target Protein Ligand Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family. (+)-JQ1 suppresses cell proliferation via inducing autophagy.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)		 BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  MlG2R4VtdCCYaXHibYxqfHliQYPzZZk> MV:yOVAwPTByL{GwNFAhdk1? M3TUTlI1NzR6L{eyJIg> M2qyUWROW09? MWrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MUGyOlcxPzh6MR?=
BCPAP NFPEOINE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NIHMUnUzPTBxNUCwM|ExODBibl2= MmjwNlQwPDhxN{KgbC=> MlXRSG1UVw>? MVjpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NUjjSpk{OjZ5MEe4PFE>
K1  MYXD[YxtKEO7Y3zlJGF{e2G7 NXHSOVBIOjVyL{WwNE8yODByIH7N MlfSO|IhcA>? M2W2fmROW09? M13nPYFzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= MoPTNlY4ODd6OEG=
BCPAP MWTD[YxtKEO7Y3zlJGF{e2G7 M3vjSFI2OC93MECvNVAxOCCwTR?= M3;KclczKGh? NXHIVXdHTE2VTx?= M{TiO4FzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= M1XhUVI3PzB5OEix
Hep3B MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\iZpAxNTFyIN88US=> MUm1JIQ> MlK5SG1UVw>? NFu2TopKSzVyPUCuNFgh|ryP MnnNNlY2PzVzNke=
HCCLM3 M1\VU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU[wMVExKM7:TR?= MWS1JIQ> NIrpR2pFVVOR NUOyZ2NiUUN3ME2wMlE1KM7:TR?= M13kT|I3PTd3MU[3
HuH7 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6wMVExKM7:TR?= NWj4e2FvPSCm MV\EUXNQ MXvJR|UxRTBwMkGg{txO NGTxdYYzPjV5NUG2Oy=>
HepG2 MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LLTFAuOTBizszN NVHDeXJDPSCm M2D2PWROW09? MX\JR|UxRTBwM{Sg{txO NIXEPFczPjV5NUG2Oy=>
SMMC7721 NF;xVWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPUNE0yOCEQvF2= M3PzN|Uh\A>? NWL3VVlUTE2VTx?= MVHJR|UxRTBwNEGg{txO NUTuV5cxOjZ3N{WxOlc>
BEL7402 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLlNE0yOCEQvF2= M2TzRlUh\A>? MWDEUXNQ M1TKd2lEPTB;MD60O{DPxE1? NWS1[3I5OjZ3N{WxOlc>
MHCC97H MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7sNE0yOCEQvF2= MVO1JIQ> NHfHe3JFVVOR NWSyTllNUUN3ME2wMlQyKM7:TR?= NVHoW4loOjZ3N{WxOlc>
Hep3B MXXD[YxtKEO7Y3zlJGF{e2G7 NI\WVYoxNjFxMD61M|IvPSEQvF2= MXm0PEBp NVvmW3l{TE2VTx?= M{fEZoxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKEiFQzDj[YxteyCrbjDzeYIuTzFicHjhd4XDqA>? M3zrV|I3PTd3MU[3
HCCLM3 MlrmR4VtdCCFeXPs[UBCe3OjeR?= MYGwMlEwOC53L{KuOUDPxE1? MXO0PEBp NUT3eJppTE2VTx?= NV\4fHlodGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZiSFPDJINmdGy|IHnuJJN2[i2JMTDwbIF{\cLi NYPFU5g3OjZ3N{WxOlc>
Hep3B NFzpVGFCeG:ydH;zbZMhSXO|YYm= MomyNE4yNzBwNT:yMlUh|ryP NGS1PXE1QCCq NVnXWnZKTE2VTx?= NGHtOphi[3SrdnH0[ZMh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUmg[ZhxemW|c3nvckBidmRiaX7keYNm\CCSQWLQJINt\WG4YXflJIF{KHenbHygZZMh[3m2b3Podo9u\SClIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOvIH\yc40hdWm2b3Poc45lemmj M4\PcVI3PTd3MU[3
HCCLM3 MV\BdI9xfG:|aYOgRZN{[Xl? MXuwMlEwOC53L{KuOUDPxE1? M1rreFQ5KGh? MV7EUXNQ MYrhZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli M4P0S|I3PTd3MU[3
A549 Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2wMlEuOTBizszN M{TrT|czKGh? MlH5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2npbFI3PDF3MkK1
H157 NWHCTpBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKwMlEuOTBizszN MUO3NkBp M3X6bIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2TCWFI3PDF3MkK1
H1299 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXIbGExNjFvMUCg{txO NWS0UlFtPzJiaB?= Ml[5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1ezcVI3PDF3MkK1
A549 Mk[2SpVv[3Srb36gRZN{[Xl? M4m1R|EwOi53L{Wg{txO NITMPFYyOiCq MkHaxsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? Mli5NlY1OTV{MkW=
H1299 MVLGeY5kfGmxbjDBd5NigQ>? NHP1TIMyNzJwNT:1JO69VQ>? NIizNVEyOiCq Mn7OxsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? MVmyOlQyPTJ{NR?=
H157 NFXFbmhHfW6ldHnvckBCe3OjeR?= MorjNU8zNjVxNTFOwG0> NGnHRWMyOiCq NGTkcVNl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= M33lRlI3PDF3MkK1
H1299 NHj5R|JHfW6ldHnvckBCe3OjeR?= NXPq[IxyOS9{LkWvOUDPxE1? MVWxNkBp NEHWUHFl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= M1HFTlI3PDF3MkK1
C8161 Mkn0R4VtdCCYaXHibYxqfHliQYPzZZk> MYOwMVIh|ryP MWC0JIQ> M{HCcmROW09? M4XYdIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4rCRlI3Ozl5MkKz
Mel285 MmPUR4VtdCCYaXHibYxqfHliQYPzZZk> MnLXNE0zKM7:TR?= M3zBUlQh\A>? MYXEUXNQ NX;4PGNj\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYCyOlM6PzJ{Mx?=
Mel290 NIXXb2dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGHIZoQxNTJizszN MXW0JIQ> NHzSWm1FVVOR MkHm[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NIXO[lczPjN7N{KyNy=>
92.1 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYjMWZh6OC1{IN88US=> NVn4[pF3PCCm MXrEUXNQ NXLaT4hP\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MWSyOlM6PzJ{Mx?=
Omm1.3 MXfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3XJfFAuOiEQvF2= NUnLUpJiPCCm NUfjVZhsTE2VTx?= M2ewVYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWSyOlM6PzJ{Mx?=
Mel202 MkfpR4VtdCCYaXHibYxqfHliQYPzZZk> MlrtNE0zKM7:TR?= M4TIdFQh\A>? NYTmNGRxTE2VTx?= MWfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3LJdFI3Ozl5MkKz
Mel270 M4HJdmNmdGxiVnnhZoltcXS7IFHzd4F6 NV;tdJFsOC1{IN88US=> NGnac2Y1KGR? MUnEUXNQ NGfXfpll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFT5fm0zPjN7N{KyNy=>
Omm1 NHfUWXFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1fOOVAuOiEQvF2= MYK0JIQ> M{K1NGROW09? M37ae4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MX:yOlM6PzJ{Mx?=
92.1 M4nw[2Fxd3C2b4Ppd{BCe3OjeR?= NFnvXZM2ODBibl2= NHP1XoY1QCCq NX;4VZgyTE2VTx?= NHPWUYRqdmS3Y3XzJIFxd3C2b4Ppdy=> M4nlfVI3Ozl5MkKz
Omm1.3 M3L0UWFxd3C2b4Ppd{BCe3OjeR?= Ml\jOVAxKG6P MUe0PEBp M3\SUmROW09? Ml21bY5lfWOnczDhdI9xfG:|aYO= MWWyOlM6PzJ{Mx?=
92.1 MW\D[YxtKEO7Y3zlJGF{e2G7 NW\COGhNPTByIH7N MY[yOE81QC95MjDo NELhOFdFVVOR Mm\ubY5lfWOnczD0bIUh[2WubDDhZ4N2dXWuYYTpc44h[XRic4XiMWcyyqB? M4O1fVI3Ozl5MkKz
Omm1.3 M3;xTmNmdGxiQ4njcIUhSXO|YYm= M2Hre|UxOCCwTR?= MWSyOE81QC95MjDo M1m3R2ROW09? NETiTlVqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?= NGm3XpYzPjN7N{KyNy=>
A549 NF;GfIJHfW6ldHnvckBCe3OjeR?= NIP4[nAyODBxNECwM|ExODBibl2= NHPaRYMzPCCq M1n3RpVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? M37ZT|I3OjF{MUm5
MCF-7 NEfJPWNHfW6ldHnvckBCe3OjeR?= NEnjRoIyODBxNECwM|ExODBibl2= NH31OVIzPCCq MlHVeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? MnLCNlYzOTJzOUm=
HEK293 M1\neGZ2dmO2aX;uJGF{e2G7 MnLiNVAxNzRyMD:xNFAxKG6P NFv1TZkzPCCq NF7WToZ2eHKnZ4XsZZRmeyCjbnSgZYN1cX[jdHXzJHNKWlRz NXfFWo5qOjZ{MUKxPVk>
858 MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUOwMVEh|ryP M2XH[VUh\A>? MYLEUXNQ MWrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MlrJNlYzODZ|M{O=
DDR2L63V NF61d2ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NX;xXnpOOC1zIN88US=> NWjQPWxrPSCm NITJSYxFVVOR NI[5PXFl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYr6SZNQOjZ{ME[zN|M>
BE(2)-C NG[0SmRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHHQU3QyKM7:TR?= NV3xZnFpOS12IHS= NVKyT4Zb\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? M{e0OVI3ODZ5NE[0
IMR-32 M3zvSmNmdGxiVnnhZoltcXS7IFHzd4F6 MmrBNUDPxE1? Mn;KNU01KGR? NH\uVY9l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MY[yOlA3PzR4NB?=
JF M{f6RWNmdGxiVnnhZoltcXS7IFHzd4F6 MX6xJO69VQ>? MV[xMVQh\A>? MVTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> MYGyOlA3PzR4NB?=
BE(2)-M17 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUKxJO69VQ>? MoTMNU01KGR? NVXXdmpW\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NIPSepEzPjB4N{S2OC=>
SK-N-SH M3v5fmNmdGxiVnnhZoltcXS7IFHzd4F6 NEG4PGMyKM7:TR?= M4SwcFEuPCCm MVrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> NYr3ZppFOjZyNke0OlQ>
SK-N-DZ  Mn;ER4VtdCCYaXHibYxqfHliQYPzZZk> MYmxJO69VQ>? M{W4[VEuPCCm NGPyXINl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NYjjUYx{OjZyNke0OlQ>
HMC-1.1  NIDIW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUm1MVUxODBibl2= M4L6cVQ5KGh? NV7STZV6TE2VTx?= MmHYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYHlOIRUOjZyNUWzNFM>
HMC-1.2 NVe2XGl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\wdoxUPS13MECwJI5O MlrHOFghcA>? NHHHWpBFVVOR Mnr6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUnUdm5IOjZyNUWzNFM>
ROSA KIT WT  NV;aeFF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3IXoJ1PS13MECwJI5O NITaZpA1QCCq NYLFeGRtTE2VTx?= MnjLbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NIHNTnkzPjB3NUOwNy=>
ROSA KIT D816V MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X1TVUuPTByMDDuUS=> MWK0PEBp M2D2XWROW09? M4LWNYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3vjWlI3ODV3M{Cz
HMC-1.1  MWfBdI9xfG:|aYOgRZN{[Xl? MmK0NlAxNTVyMECgcm0> MVS0PEBp Ml;mSG1UVw>? NUPuT3RDcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MY[yOlA2PTNyMx?=
HMC-1.2 MV\BdI9xfG:|aYOgRZN{[Xl? M3TDXlIxOC13MECwJI5O M17ndVQ5KGh? NFO4XJRFVVOR MYHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{PQdlI3ODV3M{Cz
ROSA KIT WT  MW\BdI9xfG:|aYOgRZN{[Xl? Mk[4NlAxNTVyMECgcm0> MkG4OFghcA>? M1HhdWROW09? Mn;CbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVGyOlA2PTNyMx?=
ROSA KIT D816V MWHBdI9xfG:|aYOgRZN{[Xl? NYjR[Y1VOjByLUWwNFAhdk1? NWjwPW9VPDhiaB?= M{Hpe2ROW09? M{LyTYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MnzPNlYxPTV|MEO=
494H NHX5c|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLWdHY4OiCq MVLEUXNQ NFfkRohKSzVyPUCuNVIzyrFyLkCwOEDPxE1? Moe2NlU6PDR3Nk[=
493H NXfufZpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXySJA4OiCq NVHxRotITE2VTx?= MU\JR|UxRTBwMES3xtExNjByOTFOwG0> NHfKco0zPTl2NEW2Oi=>
716H NFvhS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVu3NkBp M{LMb2ROW09? NX31elc1UUN3ME2wMlIyOsLzMD6wN|Qh|ryP M{TWVlI2QTR2NU[2
148I MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjMfHY4OiCq MVPEUXNQ NEXCOFJKSzVyPUCuNlg1yrFyLkCzOUDPxE1? M4\TdVI2QTR2NU[2
98Sc NVrSeZNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD2TlloPzJiaB?= MnO2SG1UVw>? NVOxcJFNUUN3ME2wMlEyPcLzMD6wNFQh|ryP M{TkZ|I2QTR2NU[2
89R MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIeydYk4OiCq NELrZYVFVVOR MWjJR|UxRTBwMUK2xtExNjByMzFOwG0> MWeyOVk1PDV4Nh?=
494L M{Xj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLIW|VyPzJiaB?= NVXQO3h5TE2VTx?= NGfaTohKSzVyPUCuN|E4yrFyLkCxNkDPxE1? NGDySJozPTl2NEW2Oi=>
493L MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzjNnY4OiCq MknLSG1UVw>? NX;VSVIyUUN3ME2wMlA2OMLzMD6wNVEh|ryP MnPPNlU6PDR3Nk[=
148L M4LIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L5OFczKGh? MnXHSG1UVw>? NWPWbZRCUUN3ME2wMlE1PsLzMD6wNVch|ryP NWjO[5JHOjV7NES1OlY>
98L MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXJdVU4OiCq MoPUSG1UVw>? NIXUW3ZKSzVyPUCuN|A6yrFyLkCyPUDPxE1? M4nhblI2QTR2NU[2
OS17 NVnKWJhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG0NpNYPzJiaB?= MkDVSG1UVw>? MUTJR|UxRTBwMEe5xtExNjByMzFOwG0> NIfte4YzPTl2NEW2Oi=>
OS9 MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIS1Tno4OiCq MlzxSG1UVw>? NFnidG9KSzVyPUCuOFA3yrFyLkCyPEDPxE1? MX:yOVk1PDV4Nh?=
MG63 MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[3NkBp NFXmOW9FVVOR NIrMOnZKSzVyPUCuNVE1yrFyLkCyOUDPxE1? NIfq[G0zPTl2NEW2Oi=>
SAOS2 Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjucFk4OiCq NISw[|hFVVOR Mm\yTWM2OD1yLkKxO:KyOC5yMEOg{txO NVTxVpoxOjV7NES1OlY>
U2OS MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nDdlczKGh? MYLEUXNQ Ml;XTWM2OD1yLkG5POKyOC5yMEig{txO NF7DV5MzPTl2NEW2Oi=>
SJSA-1 NFL0eo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTEO|IhcA>? NF:3PW9FVVOR NGLBb3pKSzVyPUCuNVAxyrFyLkCxNEDPxE1? MnnHNlU6PDR3Nk[=
494H Mkm1RZBweHSxc3nzJGF{e2G7 NF;LNVcxNjJ3L{CuOU8yNjBizszN NHr2WmszPCCq NUP2Wo5JTE2VTx?= MXLpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MWOyOVk1PDV4Nh?=
148I MXLBdI9xfG:|aYOgRZN{[Xl? NUKyV|hrOC5{NT:wMlUwOS5yIN88US=> M2H3flI1KGh? NWnGboNmTE2VTx?= M1u2N4lv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? MkW4NlU6PDR3Nk[=
OS17 M{PTNmFxd3C2b4Ppd{BCe3OjeR?= MlH4NE4zPS9yLkWvNU4xKM7:TR?= NGnyboszPCCq MVvEUXNQ MVPpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> MUiyOVk1PDV4Nh?=
494H MYPBdI9xfG:|aYOgRZN{[Xl? M{PNXVHjiIoQvF2= NFX1bWg1QCCq MnzwSG1UVw>? M4XJe4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> MUWyOVk1PDV4Nh?=
148I M{LpPWFxd3C2b4Ppd{BCe3OjeR?= M1TaVVHjiIoQvF2= NEe1NmE1QCCq MVjEUXNQ NEjnWotqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IIPp[45q\mmlYX70cJk> NFv1ZZAzPTl2NEW2Oi=>
OS17 NYX2OVZVSXCxcITvd4l{KEG|c3H5 MlnDNgKBkc7:TR?= NVrhZYtpPDhiaB?= NVy3UpI5TE2VTx?= NXm5UXhucW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NV\ESnBTOjV7NES1OlY>
MOLM13 NYLIVFA3SXCxcITvd4l{KEG|c3H5 MkH3NlUxKG6P M{f2WVQ5KGh? MV3EUXNQ NHPOW49qdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= MoL6NlUxPTN6MkW=
MV4-11  MYLBdI9xfG:|aYOgRZN{[Xl? NV3hVHpuOjVyIH7N NWDlOJRKPDhiaB?= Mni3SG1UVw>? MmPwbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk NEDNOFgzPTB3M{iyOS=>
MOLM13 M3jPfGZ2dmO2aX;uJGF{e2G7 NHj0UIEzPTBibl2= M4rjelI1KGh? MWjEUXNQ NYfUdnZR\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ NIDxbHAzPTB3M{iyOS=>
MV4-11  NWCyeHg5TnWwY4Tpc44hSXO|YYm= M1TPOlI2OCCwTR?= NH7oNHIzPCCq NHTW[pVFVVOR MoLy[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS Mnq3NlUxPTN6MkW=
MOLM13 NHLsTVNCeG:ydH;zbZMhSXO|YYm= Mkj2NlUxKG6P NFe4RZc1QCCq NUDtT5ZYTE2VTx?= NVv0NpVKcW6mdXPld{B{cWewaX\pZ4FvfGy7IHHwc5B1d3OrczDjc5Rz\WG2bXXueEB4cXSqIIDvcoF1cW6rYh?= NFe3OYczPTB3M{iyOS=>
MV4-11  MXHBdI9xfG:|aYOgRZN{[Xl? M1LvZVI2OCCwTR?= NEnaWno1QCCq NEnJd5dFVVOR MXTpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheG:wYYTpcolj MVmyOVA2Ozh{NR?=
Hela MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHvDPW4xNTVyMDDuUS=> NUTqWohOPzJiaB?= MX7EUXNQ M1vFSIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYHQfGpqOjVyMEmyPVU>
HBL-1 MmPLR4VtdCCYaXHibYxqfHliQYPzZZk> NHHaUJMxNTVyMDDuUS=> NHr5VW84OiCq NXzjc3ZvTE2VTx?= M335W4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NI\zdpUzPTByOUK5OS=>
HLY-1 Mlz1R4VtdCCYaXHibYxqfHliQYPzZZk> MWewMVUxOCCwTR?= MVK3NkBp MYjEUXNQ Momy[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mm\LNlUxODl{OUW=
OCI-Ly3 MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFzoe5ExNTVyMDDuUS=> MW[3NkBp NGPw[21FVVOR MXzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUiyOVAxQTJ7NR?=
OCI-Ly10 Mne1R4VtdCCYaXHibYxqfHliQYPzZZk> MV2wMVUxOCCwTR?= MXS3NkBp NGLaTIFFVVOR NH3iRpJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHj4XFczPTByOUK5OS=>
SU-DHL-4 MoPiR4VtdCCYaXHibYxqfHliQYPzZZk> NG[3ZYQxNTVyMDDuUS=> NYC3[HpLPzJiaB?= NYXN[ZZFTE2VTx?= NILRTZZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGLmbXczPTByOUK5OS=>
SU-DHL-5 M4XBUGNmdGxiVnnhZoltcXS7IFHzd4F6 NYruUmh4OC13MECgcm0> M3nG[lczKGh? MoPwSG1UVw>? NVy5eYxT\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M2L1[|I2ODB7Mkm1
SU-DHL-6 M3;PdGNmdGxiVnnhZoltcXS7IFHzd4F6 M2XtTlAuPTByIH7N M{\2WlczKGh? M13XUmROW09? MljV[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4TpTlI2ODB7Mkm1
SU-DHL-10 NXrmXoQzS2WubDDWbYFjcWyrdImgRZN{[Xl? NGHJfIkxNTVyMDDuUS=> NV36ZXR6PzJiaB?= MkjhSG1UVw>? M4PrUYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYOyOVAxQTJ7NR?=
RC-K8 M2XqR2NmdGxiVnnhZoltcXS7IFHzd4F6 MYOwMVUxOCCwTR?= NGPPeno4OiCq NYLtemhxTE2VTx?= NYG4UGRN\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYDSZoVUOjVyMEmyPVU>
OCI-Ly8 NVHMe2VxS2WubDDWbYFjcWyrdImgRZN{[Xl? NVOxWVR[OC13MECgcm0> MoPRO|IhcA>? M1[zSGROW09? M1LObYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MVOyOVAxQTJ7NR?=
OCL-Ly18 MoDKR4VtdCCYaXHibYxqfHliQYPzZZk> NITJflUxNTVyMDDuUS=> MlTqO|IhcA>? MmDnSG1UVw>? NYDmT4pC\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWPnXXV[OjVyMEmyPVU>
OCI-Ly3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVyxO|IwOjVyL{WwNEBvVQ>? MYCyM|ch\A>? MWjEUXNQ MmHHbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= M3zCSlI2ODB7Mkm1
OCI-Ly8 MnjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3pNVczNzJ3MD:1NFAhdk1? NEjjZnczNzdiZB?= MmL5SG1UVw>? NX3qWWJ[cW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> M2jKTlI2ODB7Mkm1
SU-DHL-4 NXzKNXJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKxO|IwOjVyL{WwNEBvVQ>? Mlu4Nk84KGR? NFPJOJdFVVOR M2C0XYlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= M4LufFI2ODB7Mkm1
SU-DHL-10 NGjWV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjkTGszOTd{L{K1NE82ODBibl2= NHrXW5MzNzdiZB?= M2\2SWROW09? MoLQbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= M4DOSFI2ODB7Mkm1
OCI-Ly3 MUnBdI9xfG:|aYOgRZN{[Xl? MV[xO|IwOjVyIH7N NWPBRpBIP2R? MnvnSG1UVw>? MUTpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= MUCyOVAxQTJ7NR?=
OCI-Ly8 NF\4cZdCeG:ydH;zbZMhSXO|YYm= NGrZe2oyPzJxMkWwJI5O MWq3[C=> NUG3S29CTE2VTx?= MnfmbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NITtcVQzPTByOUK5OS=>
SU-DHL-4 NGfWeoRCeG:ydH;zbZMhSXO|YYm= MorrNVczNzJ3MDDuUS=> NHPQb5U4\A>? MUPEUXNQ NHPyZm1qdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> MontNlUxODl{OUW=
SU-DHL-10 MXrBdI9xfG:|aYOgRZN{[Xl? NH;OXmwyPzJxMkWwJI5O MlrkO4Q> NEKzPI9FVVOR MmHBbY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MnHwNlUxODl{OUW=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
pDNA-PKcs / γH2AX / Ub-γH2AX / p-c-Jun S63 / Bax; 

PubMed: 26119999     


The comparative effects of the active (+)-JQ1 vs. the inactive (−)-JQ1 on the cellular responsiveness to radiation and the cell fate decision. 

c-Myc; 

PubMed: 23792448     


PEL and non-PEL (Namalwa) cells treated with indicated doses of (+)-JQ1 for 48 hours were lysed and analyzed by Western blot for the expression of c-Myc. GAPDH was used as a loading control. 

p27; 

PubMed: 23792448     


Western blot analysis showing induction of p27 upon 48 hours of treatment with (+)-JQ1. GAPDH serves as a loading control.

26119999 23792448
Growth inhibition assay
Cell viability; 

PubMed: 23792448     


PEL cell lines (BC1, BC3, BCBL1 and JSC1) were treated with indicated doses of (-)-JQ1 or (+)-JQ1 for 5 days and cell viability measured using an MTS assay (refer to Materials and methods). Namalwa, a Burkitt's lymphoma cell line, was used as a control. 

23792448
Immunofluorescence
GM130; 

PubMed: 29074567     


Representative images of A549cells treated with single compounds or in combination (as indicated) are shown. 

MHC / EdU; 

PubMed: 28733670     


C2C12 cultures were switched to DM and treated with 1 µM (+)-JQ1, (−)-JQ1, DMSO or untreated (DM only). Cells were fixed at 12, 24, 48 and 72 hours after treatment and pulsed with EdU 2 hours before fixation. EdU positive nuclei were stained with Alexa Fluor 555 and cultures immunostained for MHC.

29074567 28733670
In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]
- Collapse
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]
- Collapse
  • Animal Models: Mice bearing NMC 797 xenografts
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S
CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A
Smiles CC1=C(C)C2=C(S1)[N]3C(=NN=C3C(CC(=O)OC(C)(C)C)N=C2C4=CC=C(Cl)C=C4)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

selleck catalog

Target Protein Ligand Inhibitors with Unique Features

  • Pan BET Inhibitor

    Bromosporine : Pan-BET inhibitor, BRD2, IC50=0.41 μM; BRD4, IC50=0.29 μM; BRD9, IC50=0.122 μM; CECR2, IC50=0.017 μM.

  • BET Inhibitor in Clinical Trial

    RVX-208 New : Phase II for Dyslipidemia.

  • Newest BET Inhibitor

    I-BET-762 : Inhibitor for BET proteins with IC50 of ~35 nM, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.

  • Classic BET Inhibitor

    I-BET151 (GSK1210151A) : Novel selective BET inhibitor for BRD2, BRD3 and BRD4 with IC50 of 0.5 μM, 0.25 μM, and 0.79 μM, respectively.

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID